Voriconazole
- Generic Name
- Voriconazole
- Brand Names
- Vfend, Voriconazole Hikma (previously Voriconazole Hospira), Voriconazole Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N5O
- CAS Number
- 137234-62-9
- Unique Ingredient Identifier
- JFU09I87TR
- Background
Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha ...
- Indication
For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.
- Associated Conditions
- Aspergillosis of the Central Nervous System, Aspergillosis of the Liver, Candidemia, Candidiasis, Coccidioidomycosis, Endocarditis caused by Aspergillus, Esophageal Candidiasis, Fungal Infections, Fungal meningitis caused by Exserohilum Infection, Fusarium infection, Histoplasmosis, Invasive Aspergillosis, Osteomyelitis caused by Aspergillus, Penicillium marneffei infection, Peritonitis caused by Aspergillus, Scedosporium Infection, Sinusitis aspergillus, Aspergillus endophthalmitis, Refractory Oral Candidiasis
- Associated Therapies
- -
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
- Conditions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00079222
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 600
- Registration Number
- NCT00075803
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00066599
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections
- Conditions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00059878
- Locations
- 🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Shands Cancer Center at the University of Florida Health Science Center, Gainesville, Florida, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Voriconazole to Treat Fungal Infections
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00001940
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 20
- Registration Number
- NCT00001757
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 10
- Registration Number
- NCT00001646
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Voriconazole to Prevent Systemic Fungal Infections in Children
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00005912
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 300
- Registration Number
- NCT00001810
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Blood and Marrow Transplant Clinical Research Network
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California at San Diego, La Jolla, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.